Arthneeti
All Q2 FY27 results →
AC

Acutaas Chemicals Ltd

Q2 FY27

Acutaas Chemicals Q2 Results 2026 (FY27) investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹3,349
Market cap₹27.4K Cr
P/E71.0
Updated27 Oct 2026
Read3 min read

Acutaas Chemicals Ltd Q2 FY27 key numbers

Revenue
Q2 FY27 Revenue from Operations: ₹4,369 million.

As stated in Acutaas Chemicals Ltd's Q2 FY27 investor presentation · published 27 Oct 2026. Reported figures, not investment advice.

Based on Acutaas Chemicals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 Revenue from Operations: ₹4,369 million - Year-on-Year (YoY) growth: 42.7% (Q2 FY27 vs Q2 FY26) - H1 FY27 Revenue: ₹7,666 million; YoY growth of 49.3% (H1 FY27 vs H1 FY26) - Revenue spli Q2 FY27 Financials: - EBITDA: ₹1,760 Mn, up 84.6% YoY - EBITDA Margin: 40.3%, up from 31.1% YoY - PAT: ₹1,231 Mn, up 71.4% YoY - PAT Margin: 28.2%, up from 23.5% YoY - Operating Margin:

From Acutaas Chemicals Ltd's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.

Revenue & Sales Performance

  • Q2 FY27 Revenue from Operations: ₹4,369 million
  • Year-on-Year (YoY) growth: 42.7% (Q2 FY27 vs Q2 FY26)
  • H1 FY27 Revenue: ₹7,666 million; YoY growth of 49.3% (H1 FY27 vs H1 FY26)
  • Revenue split Q2 FY27: Advance Intermediates ₹4,020 million, Specialty Chemicals ₹349 million
  • Management revised FY27 revenue growth guidance upward from 25% to around 30%

2 more points from Acutaas Chemicals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • This facility is equipped to produce high-purity chemicals for photoresists, semiconductor packaging materials, etching materials, and other semiconductor applications, targeting the semiconductor ecosystem (Page 3).
  • Capital work-in-progress assets increased notably over recent years, peaking at ₹3,324 million in FY26 and ₹669 million in H1 FY27 (Page 9), reflecting ongoing capacity expansion investments.

Fundraising & Capital Structure

See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It does mention: - "Improved revenue visibility and robust order pipeline" highlighted by the Executive Chairman in the Management Commentary on page 3. - The increased confidence in business prospects is reflected in the upward revision of FY27 revenue growth guidance from 25% to around 30% and EBITDA margin guidance to 38-40%.

Acutaas Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹437 Cr, net profit ₹123 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Acutaas Chemicals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Acutaas Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Acutaas Chemicals Ltd Q2 FY27 results?

Q2 FY27 Revenue from Operations: ₹4,369 million - Year-on-Year (YoY) growth: 42.7% (Q2 FY27 vs Q2 FY26) - H1 FY27 Revenue: ₹7,666 million; YoY growth of 49.3% (H1 FY27 vs H1 FY26) - Revenue spli Q2 FY27 Financials: - EBITDA: ₹1,760 Mn, up 84.6% YoY - EBITDA Margin: 40.3%, up from 31.1% YoY - PAT: ₹1,231 Mn, up 71.4% YoY - PAT Margin: 28.2%, up from 23.5% YoY - Operating Margin:

What is Acutaas Chemicals Ltd share price analysis?

Acutaas Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 71.0 with a market cap of ₹27,414 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.